Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea

被引:1
|
作者
Ikegami, T
Ha, L
Arimori, K
Latham, P
Kobayashi, K
Ceryak, S
Matsuzaki, Y
Bouscarel, B
机构
[1] George Washington Univ, Med Ctr, Dept Med, Washington, DC 20037 USA
[2] George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA
[3] George Washington Univ, Med Ctr, Dept Pathol, Washington, DC 20037 USA
[4] George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA
[5] Miyazaki Med Coll, Dept Pharm, Miyazaki 8891692, Japan
[6] Saitama Canc Ctr, Ina, Saitama 3360011, Japan
[7] Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3050024, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The therapeutic efficacy of irinotecan (CPT-11), a DNA topoisomerase inhibitor, is often limited by the induction of severe late-onset diarrhea. This prodrug and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), have a labile a-hydroxy-lactone ring that undergoes pH-dependent reversible hydrolysis. At physiological pH and higher, equilibrium favors the less toxic carboxylate form, whereas at acidic pH, the more potent lactone form is favored. We have reported previously that the initial uptake rate of CPT-11 and SN-38 by intestinal cells was significantly different between the respective lactone and carboxylate form. Results from the present study in HT-29 cells further demonstrate the correlation between the CPT-11/SN-38 initial uptake rate and the induced toxicity, cell cycle alteration, apoptosis, and colony-forming efficiency. The exposure of HT-29 cells to SN-38 for a limited period of time (<2 h) was sufficient to induce these events. Because the decreased initial uptake of SN-38 carboxylate resulted in a reduced cellular toxicity, we postulated that the CPT-11-induced diarrhea was preventable by influencing the equilibrium toward the carboxylate form and, thus, reducing its intestinal uptake. In the golden Syrian hamster model, p.o. sodium bicarbonate supplementation (5 mg/ml in drinking water) led to alkalization of the intestinal contents. In addition, this alkalization resulted in the reduction of the histopathological damage to the mucosa of the small and large intestine, as well as a 20% reduction of the intestinal SN-38 lactone concentration of animals receiving CPT-11 (20-50 mg/kg X 7 days). Taken together, these results from in vitro and in vivo studies support intestinal alkatization by sodium bicarbonate supplementation as a preventive mechanism against CPT-11-induced diarrhea. In addition, this provides a strong rationale for the usage of this measure as an adjunct to CPT-11 treatment.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 50 条
  • [21] Uptake mechanism of irinotecan (CPT-11) and its metabolite (SN-38) by hamster intestinal cells.
    Kobayashi, K
    Bouscarel, B
    Matsuzaki, Y
    Ceryak, S
    Fromm, H
    GASTROENTEROLOGY, 1998, 114 (04) : A626 - A627
  • [22] Contribution of human liver carboxylesterase and human intestinal carboxylesterase to the activation of Irinotecan (CPT-11)
    Hatfield, Michael
    Tsurkan, Lyudmila
    Hicks, Latorya
    Hyatt, Janice
    Edwards, Carol
    Wierdl, Monika
    Potter, Philip
    CANCER RESEARCH, 2009, 69
  • [23] Therapeutic Response to Octreotide in Patients with Refractory CPT-11 Induced Diarrhea
    Barbara Pro
    Richard Lozano
    Jaffer A. Ajani
    Investigational New Drugs, 2001, 19 : 341 - 343
  • [24] Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment
    Lenfers, BHM
    Loeffler, TM
    Droege, CM
    Hausamen, TU
    ANNALS OF ONCOLOGY, 1999, 10 (10) : 1251 - 1253
  • [25] Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea
    Pro, B
    Lozano, R
    Ajani, JA
    INVESTIGATIONAL NEW DRUGS, 2001, 19 (04) : 341 - 343
  • [26] Involvement of β-glycuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative, irinotecan (CPT-11), in rats
    Takasuna, K
    Hagiwara, T
    Kamataki, T
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R437 - R437
  • [27] Irinotecan (CPT-11) metabolites in human bile and urine
    Lokiec, F
    duSorbier, BM
    Sanderink, GJ
    CLINICAL CANCER RESEARCH, 1996, 2 (12) : 1943 - 1949
  • [28] Irinotecan (CPT-11) metabolism and disposition in cancer patients
    Sparreboom, A
    de Jonge, MJA
    de Bruijn, P
    Brouwer, E
    Nooter, K
    Loos, WJ
    van Alphen, RJ
    Mathijssen, RHJ
    Stoter, G
    Verweij, J
    CLINICAL CANCER RESEARCH, 1998, 4 (11) : 2747 - 2754
  • [29] The current status of irinotecan (CPT-11) in the United States
    Rothenberg, ML
    CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT, 1996, 803 : 272 - 281
  • [30] Future directions for clinical research with CPT-11 (irinotecan)
    VonHoff, D
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S9 - S12